ORTHOPEDIATRICS CORP - FORM 8-K - EX-99.1

Attached files

file	filename
8-K - 8-K - ORTHOPEDIATRICS CORP	kids-20210111.htm

2850 Frontier Drive Warsaw, Indiana 46582 www.orthopediatrics.com 877.268.6339 574.268.6379 574.269.3692 TOLL-FREE PHONE FAX SCOLIOSIS SPORTS MEDICINE TRAUMA & DEFORMITY CLINICAL EDUCATION OrthoPediatrics Corp. Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2020 Full year revenue up 2%, representing strong execution in an unprecedented global environment WARSAW, Indiana, January 11, 2021 — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2020. Preliminary unaudited fourth quarter 2020 revenue is expected to be $21.7 million, up 14%, when compared to $19.0 million in the fourth quarter of 2019. Preliminary domestic revenue grew 26% while international revenue declined 21%. OrthoPediatrics’ preliminary unaudited full year 2020 revenue is expected to be $73.8 million, representing annual growth of 2%. Preliminary full year domestic revenue grew 14% while international revenue declined 38%. The Company plans to release its fourth quarter and full year 2020 financial results in early March 2021. The quarterly and annual preliminary revenue estimates for 2020 included in this press release are prior to the completion of review and audit procedures by the Company’s independent registered public accounting firm and are therefore subject to adjustment. Forward‐Looking Statements This press release includes "forward‐looking statements" within the meaning of U.S. federal securities laws, including the statements regarding OrthoPediatrics’ preliminary revenue for the fourth quarter and full year ended December 31, 2020, and other statements identified by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential," "objective," "would" and other similar expressions. Forward‐looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics’ control. Important factors could cause actual results to differ materially from those in the forward‐looking statements, including, among others: the risks related to COVID‐19, the continued impact such pandemic may have on the demand for our products, and our ability to respond to the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10‐K filed with the Securities and Exchange Commission (the "SEC") on March 5, 2020, as updated and supplemented by our other SEC reports filed from time to time. Forward‐looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward‐looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws. About OrthoPediatrics Corp. Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit www.orthopediatrics.com. Investor Contacts The Ruth Group

ORTHOPEDIATRICS CORP - FORM 8-K - EX-99.1 - January 11, 2021

Attached files

ORTHOPEDIATRICS CORP Reports